Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 2 3Phase 1/2 1

Status

Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 19Thoracic 3Genitourinary 3Breast 3Gynecologic 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1

Conditions

Breast Neoplasms 3

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 215Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Radiofrequency Ablation × Breast × Clear all
NCT04698252 2022-08-08

LARA

Instituto do Cancer do Estado de São Paulo

Phase 2 Recruiting
74 enrolled
Breast

Breast Neoplasms

NCT03750396 2019-02-15

CLEAR

Gangnam Severance Hospital

Phase 2 Unknown
110 enrolled
Breast

Breast Neoplasms

NCT00373152 2017-12-05

MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡